| Nov 19 |
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
|
| Nov 7 |
Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.87
|
| Nov 7 |
Cidara Therapeutics: Q3 Earnings Snapshot
|
| Oct 31 |
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
|
| Oct 16 |
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
|
| Oct 4 |
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
|
| Sep 25 |
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
|
| Sep 23 |
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
|
| Sep 19 |
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
|
| Sep 13 |
Cidara axes 30% of staff to focus on flu prevention drug
|
